Clinical Trial: Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome
Brief Summary:
- Clinical Objective : To improve the growth of these children
- Genetic objective : A study of the genetics of the syndrome
Detailed Summary:
Sponsor: Sanofi
Current Primary Outcome: Evaluation of height : gain in height and rate of growth [ Time Frame: at each visit (every 3 months) or every 6 months ]
Original Primary Outcome: Evaluation of height : gain in height and rate of growth
Current Secondary Outcome: Clinical and laboratory test safety [ Time Frame: every 6 months ]
Original Secondary Outcome: Clinical and laboratory test safety
Information By: Sanofi
Dates:
Date Received: March 23, 2007
Date Started: October 1997
Date Completion:
Last Updated: October 4, 2010
Last Verified: October 2010
